Cullinan Therapeutics宣布，其研发管线中的两项关键资产即将迎来新的临床数据更新。公司预计，针对自身免疫性疾病候选药物CLN-978，将在下一季度获得用于治疗类风湿关节炎（RA）的额外多剂量数据，而针对系统性红斑狼疮（SLE）的同类数据则计划于今年第四季度公布。此外，另一款在研药物velinotamig的额外临床数据也有望在年底前获得。这些数据节点对于评估药物的安全性和有效性至关重要，或将影响公司未来的研发决策与合作伙伴的洽谈。
Cullinan Therapeutics宣布，其研发管线中的两项关键资产即将迎来新的临床数据更新。公司预计，针对自身免疫性疾病候选药物CLN-978，将在下一季度获得用于治疗类风湿关节炎（RA）的额外多剂量数据，而针对系统性红斑狼疮（SLE）的同类数据则计划于今年第四季度公布。此外，另一款在研药物velinotamig的额外临床数据也有望在年底前获得。这些数据节点对于评估药物的安全性和有效性至关重要，或将影响公司未来的研发决策与合作伙伴的洽谈。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.